Published 1 day ago • loading... • Updated 1 day ago

Cogent Reports Positive Topline Results From SUMMIT Trial of Bezuclastinib in NonAdvSM - BioTuesdays

Cogent Biosciences (NASDAQ: COGT) has announced positive topline results from the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM), achieving statistical significance across all primary and secondary endpoints. According to Cogent, based on these results, the company is on track to submit its first new drug application (NDA) to the FDA for bezuclastinib in NonAdvSM by the end of 2025. Additionally, Cog…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

biotuesdays.com

Cogent reports positive topline results from SUMMIT trial of bezuclastinib in NonAdvSM - BioTuesdays

1 day ago

Read Full Article

endpoints.news

Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial

Cogent Biosciences said it’s working on an FDA submission for its systemic mastocytosis (SM) drug after breezing through a Phase 2 test in an indolent form of the disease. The biotech’s bezuclastinib achieved an average ...

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right